Pain and Opioids: Integrated Treatment In Veterans
Key facts
- Who runs it
- University of New Mexico
- Where
- Albuquerque, San Francisco, and Tacoma, United StatesSee the 4 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 157 people enrolled
- Started
- 1 Jul 2021
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ACT+MBRP
- Education control
- Record updated
- 30 October 2026
Who can take part
- Age
- 21 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Stabilized on a dose of buprenorphine for a period of at least 1 month and less than six months. Buprenorphine stabilization will be defined as a consistent dose for at least 30 consecutive days
- Willing to comply with all study procedures and be available for the duration of the study
- Male or female, aged 21 to 75 years
- Enrolled as a patient in one of the participating VA Co-Occurring Disorders clinics
- Presence of chronic pain for > 6 months in duration
Who cannot take part
- Current or past diagnosis of schizophrenia, delusional disorder, psychotic or dissociative disorders
- Have a substance use disorder requiring a higher level of care than outpatient treatment (e.g., severe alcohol use disorder requiring inpatient detoxification)
- Unable to read English
Where in United States
- New Mexico VA Healthcare SystemAlbuquerque, United States
- University of New MexicoAlbuquerque, United States
- San Francisco VA Health Care SystemSan Francisco, United States
- Puget Sound VA Healthcare SystemTacoma, United States
About the trial
What the trial wants to find out
This trial will recruit veterans with chronic pain (N = 160) who are prescribed buprenorphine for the treatment of opioid use disorder (OUD). We seek to: (1) examine the efficacy of an integrated treatment to reduce pain interference (Acceptance and Commitment Therapy and Mindfulness-Based Relapse Prevention [ACT + MBRP]) compared to an education control (EC) consisting of a protocol-based series of education sessions concerning chronic pain, opioids, and buprenorphine use and (2) examine how theoretically-relevant treatment mechanisms of pain acceptance, engagement in values-based action, and opioid craving are related to treatment outcomes. Interventions will be delivered via the VA Video Connect telehealth modality.
The 2 groups in the trial
- ACT + MBRPTreatment being tested
Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) group will follow a manualized clinical protocol. Treatment will include 12 weekly group-based sessions, each lasting 90 minutes. Group sizes will range from 3 to 8. ACT + MBRP will be delivered via the VA Video Connect telehealth platform.
- Education Control (EC)Existing treatment, for comparison
The EC group will follow a protocol that combines opioid education sessions and psychology-led pain education sessions that are offered as part of the interdisciplinary pain program. Specifically, education will include 12 group-based sessions, each lasting 60 to 90 minutes. Group sizes will range from 3 to 8. EC will be delivered via the VA Video Connect telehealth platform.
Treatment: Education control
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Integrated Treatment for Veterans With Co-Occurring Chronic Pain and Opioid Use Disorder
- Record updated
- 30 October 2026